Merck announced on November 20, 2026, that its phase 3 TroFuse-015 trial of sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate (ADC), met its primary end point of overall survival (OS) in patients with locally advanced unresectable or metastatic gastroesophageal adenocarcinoma who had received 2 or more prior lines of systemic therapy.¹ Merck said in a company press release that the trial is the first time a TROP2-directed ADC has shown an OS benefit in a global phase 3 trial in this population.¹
Key facts
- Drug: sacituzumab tirumotecan (sac-TMT; Merck, licensed from Kelun-Biotech)
- Class: TROP2-directed antibody-drug conjugate (belotecan-derived topoisomerase I inhibitor payload)
- Indication studied: Locally advanced unresectable or metastatic gastroesophageal adenocarcinoma, third line or later
- Trial: TroFuse-015 (NCT06356311); phase 3, randomized, open-label, n=473
- Comparator: Treatment of physician's choice (trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel)
- Dosing: 4 mg/kg on days 1, 15, and 29 of each 6-week cycle
- Primary end point met: Overall survival; numeric results not disclosed
- Secondary end points: Progression-free survival not met; response rate nominally favored sac-TMT
- Safety: No new safety signals
- Program: 18 ongoing global phase 3 trials; second positive phase 3 readout
“There is a tremendous unmet need for therapies that can improve survival for these patients,” said Marjorie Green, MD, senior vice president and head of oncology, global clinical development, at Merck Research Laboratories, in the release.¹
Did sacituzumab tirumotecan improve overall survival in gastroesophageal cancer?
At final analysis, sac-TMT produced a statistically significant and clinically meaningful improvement in OS compared with treatment of physician's choice (TPC), and results were generally consistent across subgroups regardless of TROP2 expression status.¹ Sac-TMT did not meet the secondary end point of progression-free survival assessed by blinded independent central review.¹ Objective response rate, another secondary end point, nominally favored sac-TMT, but that comparison was not formally tested under the prespecified analysis plan.¹ The safety profile was consistent with previously reported sac-TMT studies, with no new safety signals.¹ Merck did not disclose numeric results, which it said will be presented at an upcoming medical meeting and shared with regulatory authorities.¹
How is the TroFuse-015 trial structured and who participated?
TroFuse-015 (NCT06356311) is a randomized, open-label, multicenter global trial that enrolled 473 patients.¹ Participants received either sac-TMT at 4 mg/kg on days 1, 15, and 29 of each 6-week cycle, or TPC consisting of trifluridine-tipiracil, irinotecan, paclitaxel, or docetaxel.¹ Secondary end points include progression-free survival, objective response rate, and duration of response.¹
How does sac-TMT work?
Sac-TMT is a TROP2-directed ADC with a belotecan-derived topoisomerase I inhibitor payload and a bifunctional linker designed to maximize payload delivery to tumor cells and limit payload loss in circulation.¹ TROP2 is overexpressed on tumor cells compared with healthy cells in many common cancers.¹ Kelun-Biotech developed the molecule and granted Merck exclusive rights to develop, manufacture, and commercialize it outside Greater China.¹
What other cancers is sacituzumab tirumotecan being tested for?
TroFuse-015 is the second positive phase 3 readout from the TroFuse program, which comprises 18 ongoing global phase 3 trials spanning more than 9 disease areas and more than 15,000 patients.¹ Merck said 14 of the 18 studies pursue first-in-class opportunities.¹ In the TroFuse-005 trial in 776 patients with previously treated endometrial cancer, sac-TMT extended median OS to 19.0 months vs 12.1 months with chemotherapy (hazard ratio [HR], 0.68; 95% confidence interval [CI], 0.55-0.84; P<.0001) and median progression-free survival to 7.2 months vs 3.9 months.² Those data were published in The Lancet, and FDA accepted a biologics license application with a target action date of June 15, 2027.²